Real-world progression-free survival in first-line advanced non-small cell lung cancer treated with immunotherapy-based regimens using a US dataset

While results from clinical trials are important in determining the efficacy of treatment, restrictive eligibility criteria may limit generalizability to patient populations in the real-world setting. Real-world analyses can therefore identify subgroups of patients who may respond differently to spe...

Descripción completa

Detalles Bibliográficos
Autores principales: Waterhouse, David, Lam, Jenny, Betts, Keith A., Yin, Lei, Gao, Sophie, Yuan, Yong, Hartman, John, Rao, Sumati, Lubinga, Solomon, Stenehjem, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Data Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209237/
https://www.ncbi.nlm.nih.gov/pubmed/34169127
http://dx.doi.org/10.1016/j.dib.2021.107195

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209237/
https://www.ncbi.nlm.nih.gov/pubmed/34169127
http://dx.doi.org/10.1016/j.dib.2021.107195

Ejemplares similares